These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37777743)

  • 61. Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial.
    Heeger CH; Jaquet K; Thiele H; Zulkarnaen Y; Cuneo A; Haller D; Kivelitz D; Schmidt T; Krause K; Metzner A; Schneider C; Kuck KH; Bergmann MW
    EuroIntervention; 2012 Oct; 8(6):732-42. PubMed ID: 23086792
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
    Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
    J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
    Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials.
    He G; Yang G; Huang X; Luo D; Tang C; Zhang Z
    Heart Lung; 2023; 59():109-116. PubMed ID: 36801545
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
    Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
    Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study.
    Wang D; Bai L; Cui XR; Yang XH; Zhang JD
    Adv Ther; 2020 Nov; 37(11):4649-4659. PubMed ID: 32968936
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
    Harrington J; Udell JA; Jones WS; Anker SD; Bhatt DL; Petrie MC; Vedin O; Sumin M; Zwiener I; Hernandez AF; Butler J
    Am Heart J; 2022 Nov; 253():86-98. PubMed ID: 35595091
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
    Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
    J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
    Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
    Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study.
    Gamaza-Chulián S; Díaz-Retamino E; González-Testón F; Gaitero JC; Castillo MJ; Alfaro R; Rodríguez E; González-Caballero E; Martín-Santana A
    BMC Cardiovasc Disord; 2021 Sep; 21(1):456. PubMed ID: 34548011
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.
    Kohsaka S; Kumamaru H; Nishimura S; Shoji S; Nakatani E; Ichihara N; Yamamoto H; Miyachi Y; Miyata H
    J Diabetes Investig; 2021 Aug; 12(8):1452-1461. PubMed ID: 33345452
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
    Younes AM; Salem M; Maraey A; Nomigolzar S; Sewell K; Khalil M; Elzanaty A; Saeyeldin A; Dar M
    Int J Cardiol; 2022 Nov; 366():51-56. PubMed ID: 35777490
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.